<DOC>
	<DOCNO>NCT01089192</DOCNO>
	<brief_summary>Objective : To study Bioequivalence Metformin Hydrochloride Extended Release 750 mg Tablets ( Test formulation , Torrent Pharmaceuticals Ltd. , India ) Versus Glucophage XR® 750 mg Tablet ( Reference formulation , Bristol-Myers Squibb company , USA ) Healthy volunteer Fasting Conditions . Study Design : An Open-Label , Randomized , 2-Period , 2-Treatment , Crossover , Single-Dose Bioequivalence Study</brief_summary>
	<brief_title>Bioequivalence Study Metformin Hydrochloride Extended Release 750 mg Tablets Versus Glucophage XR® 750 mg Tablet Healthy Volunteers Under Fasting Conditions .</brief_title>
	<detailed_description />
	<mesh_term>Metformin</mesh_term>
	<criteria>Volunteers must meet follow criterion order include study : 1 . Sex : male . 2 . Age : 18 45 year . 3 . Volunteer BMI 1827 ( inclusive ) kg/m2 minimum 50 kg weight . 4 . Healthy willing participate study . 5 . Volunteer willing adhere protocol requirement provide write informed consent . 6 . Nonsmokers smoker smoke less 10 cigarette day . The volunteer exclude study base follow criterion : 1 . Clinically relevant abnormality result laboratory screening evaluation . 2 . Clinically significant abnormal ECG Chest Xray . 3 . Systolic blood pressure le 100 mm Hg 140 mm Hg diastolic blood pressure le 60 mm Hg 90 mm Hg . 4 . Pulse rate le 50/minute 100/minute . 5 . Oral temperature le 95°F 98.6°F . 6 . Respiratory rate le 12/minute 20/minute 7 . Addiction alcohol history drug abuse within past 2 year . 8 . Recent History kidney liver dysfunction . 9 . History allergy test drug drug chemically similar drug investigation . 10 . Administration/ Intake prescription OTC medication two week study . 11 . Patients suffer chronic illness arthritis , asthma etc . 12 . HIV , HCV , HBsAg positive volunteer . 13 . Opioids , tetra hydrocannabinoids , amphetamine , barbiturate , benzodiazepine , Cocaine positive volunteer base urine test . 14 . Volunteers suffer psychiatric ( acute chronic ) illness require medication . 15 . Administration investigational product period 0 3 month entry study . 16 . Intake barbiturate enzymeinducing drug last three month . 17 . History significant blood loss due reason , include blood donation past 12 week . The total blood loss last 3 month include study exceed 350ml . 18 . Existence surgical medical condition , , judgement Chief Investigator and/or clinical investigator , might interfere absorption , distribution , metabolism excretion drug likely compromise safety Volunteers . 19 . Inability communicate cooperate due language problem , poor mental development impair cerebral function .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2010</verification_date>
</DOC>